Literature DB >> 8861189

Neurobiological and psychopharmacological basis in the therapy of bulimia and anorexia.

M C Mauri1, R Rudelli, E Somaschini, L Roncoroni, R Papa, M Mantero, M Longhini, G Penati.   

Abstract

1. Eating disorders can be found in several psychiatric pathologies: schizophrenia, delusional disorder (somatic type), bipolar disorders, major depressive disorder, borderline personality disorder, generalized anxiety disorder, body dysmorphic disorder, somatization disorder and conversion disorder. 2. Although their clinical features have been defined, relatively little is known about the role of neurobiological patterns in the pathogenesis of these disorders. Several CNS neurotransmitters and neuromodulators are involved in the regulation of eating behavior in animals and have been implicated in symptoms such as depression and anxiety often observed in patients with eating disorders. The authors will review some studies on NA, DA, 5-HT, beta-endorphins, CRH, VP, OT, CCK, NPY and PYY involved in eating disorders. Furthermore, we will highlight some of the studies on drug therapy of eating disorders taking into account the effects of these agents on neurotransmitters and neuromodulators. 3. Antidepressant drugs have long been used for anorexia nervosa and bulimia, these disorders been claimed to be affective equivalent. Antidepressant agents seem to be effective in reducing the frequency of binge-eating episodes, purging behavior and depressive symptomatology. It is notable that antidepressant agents have been proved to be effective in patients with chronic bulimic symptoms, even in cases persisting for many years and in patients who had repeatedly failed courses of alternative therapeutic approaches. In all of the positive studies, antidepressant agents appeared effective even in bulimic subjects who did not display concomitant depression. 4. Few controlled studies on use of medications for anorexia nervosa have been published. Central serotonergic receptor-blocking compounds such as cyproheptadine cause marked increase in appetite and body weight. Zinc supplementation or cisapride could be a therapeutic option in addition to psychological and other approaches in anorexia nervosa. 5. There is no therapy as yet which is fully effective in alimentary disorders. Psychotropic drugs give some relief from symptoms, but they cannot cure the disorders. An integrated approach, either pharmacological or psychological, is still recommendable.

Entities:  

Mesh:

Year:  1996        PMID: 8861189     DOI: 10.1016/0278-5846(95)00306-1

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  4 in total

1.  Associations between the serotonin-1A receptor C(-1019)G polymorphism and disordered eating symptoms in female adolescents.

Authors:  Se-Won Lim; Juwon Ha; Dong-Won Shin; Hee-Yeon Woo; Kye-Hyun Kim
Journal:  J Neural Transm (Vienna)       Date:  2010-05-09       Impact factor: 3.575

2.  Hypophagia and induction of serotonin transporter gene expression in raphe nuclei of male and female rats after short-term fluoxetine treatment.

Authors:  Nuria Lauzurica; Luis García-García; José A Fuentes; Mercedes Delgado
Journal:  J Physiol Biochem       Date:  2012-06-23       Impact factor: 4.158

3.  Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX).

Authors:  Sunny E Ohia; Catherine A Opere; Angela M LeDay; Manashi Bagchi; Debasis Bagchi; Sidney J Stohs
Journal:  Mol Cell Biochem       Date:  2002-09       Impact factor: 3.396

4.  Super CitriMax (HCA-SX) attenuates increases in oxidative stress, inflammation, insulin resistance, and body weight in developing obese Zucker rats.

Authors:  Mohammad Asghar; Emmanuel Monjok; Ghislaine Kouamou; Sunny E Ohia; Debasis Bagchi; Mustafa F Lokhandwala
Journal:  Mol Cell Biochem       Date:  2007-05-15       Impact factor: 3.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.